How is MacroGenics Inc.’s (NASDAQ: MGNX) stock expected to perform amid current market woes?

After closing at $3.16 in the most recent trading day, MacroGenics Inc. (NASDAQ: MGNX) closed at 3.01, down -4.75%. In other words, the price has decreased by $-0.1500 from its previous closing price. On the day, 1070313 shares were traded. MGNX reached its highest trading level at $3.1200 during the session, while it also had its lowest trading level at $2.9699.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored

Ratios:

Our goal is to gain a better understanding of MGNX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.20 and its Current Ratio is at 3.30. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On July 11, 2022, BMO Capital Markets Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $31 to $4.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 15 when Karrels James bought 40,000 shares for $2.47 per share. The transaction valued at 98,800 led to the insider holds 191,776 shares of the business.

BIOTECH TARGET N V bought 200,000 shares of MGNX for $3,700,320 on Nov 19. The 10% Owner now owns 7,275,564 shares after completing the transaction at $18.50 per share. On Sep 29, another insider, BIOTECH TARGET N V, who serves as the 10% Owner of the company, bought 100,000 shares for $20.47 each. As a result, the insider paid 2,047,460 and bolstered with 7,075,564 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 2.84 while its Price-to-Book (P/B) ratio in mrq is 1.30.

Stock Price History:

Over the past 52 weeks, MGNX has reached a high of $22.68, while it has fallen to a 52-week low of $2.13. The 50-Day Moving Average of the stock is 3.9268, while the 200-Day Moving Average is calculated to be 7.6778.

Shares Statistics:

The stock has traded on average 948.19K shares per day over the past 3-months and 571.64k shares per day over the last 10 days, according to various share statistics. A total of 61.38M shares are outstanding, with a floating share count of 58.63M. Shares short for MGNX as of Jul 14, 2022 were 6.84M with a Short Ratio of 5.17, compared to 7.74M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 11.15% and a Short% of Float of 14.74%.

Earnings Estimates

Its stock is currently analyzed by 11 different market analysts. On average, analysts expect EPS of $-0.97 for the current quarter, with a high estimate of $-0.61 and a low estimate of $-1.09, while EPS last year was $-0.66. The consensus estimate for the next quarter is $-0.67, with high estimates of $0.01 and low estimates of $-1.12.

Analysts are recommending an EPS of between $-2.78 and $-3.91 for the fiscal current year, implying an average EPS of $-3.35. EPS for the following year is $-2.88, with 10 analysts recommending between $-1.77 and $-3.82.

Revenue Estimates

A total of 11 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $118.33M, while the lowest revenue estimate was $48.91M, resulting in an average revenue estimate of $82.28M. In the same quarter a year ago, actual revenue was $77.45M, up 6.20% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $90.47M in the next fiscal year. The high estimate is $127.33M and the low estimate is $13M. The average revenue growth estimate for next year is up 10.00% from the average revenue estimate for this year.